ClinicalTrials.gov
ClinicalTrials.gov Menu

PPD Size and Mycobacteria Tuberculosis ELISPOT in Children Who Have Received BCG in Neonate Period

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00172783
Recruitment Status : Unknown
Verified June 2005 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
First Posted : September 15, 2005
Last Update Posted : September 15, 2005
Sponsor:
Information provided by:
National Taiwan University Hospital

Brief Summary:
To investigate the size of PPD and TB specific ELISPOT among children between 3m/o and 15 y/o . Calculate the normal range of age specific PPD size in children who recieved BCG at new-born period.

Condition or disease
Tuberculosis

  Show Detailed Description

Study Type : Observational
Enrollment : 460 participants
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Official Title: PPD Size and Mycobacteria Tuberculosis ELISPOT in Children Who Have Received BCG in Neonate Period
Study Start Date : June 2005
Study Completion Date : December 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   3 Months to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: A healthy child with the age between 3 month to 15 year, who has received BCG in the first month of life as schedule, without history of exposure of tuberculosis. -

Exclusion Criteria: Children not received his BCG within one month after birth, immunodeficiency, received steroid or immunosuppresant within 6 weeks, severe infection within 6 weeks, received life vaccine within 6 weeks


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00172783


Contacts
Contact: Li-Ming Huang, PHD 886-2-23123456 ext 5139 lmhuang@ha.mc.ntu.edu.tw

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 100
Contact: Li-Ming Huang, MD, PHD    886-2-23123456 ext 5139    lmhuang@ha.mc.ntu.edu.tw   
Principal Investigator: Pei-Chun Chan, MD         
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Study Chair: Li-Ming Huang, MD, PHD National Taiwan University Hospital, Pediatrics

ClinicalTrials.gov Identifier: NCT00172783     History of Changes
Other Study ID Numbers: 940201
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: September 15, 2005
Last Verified: June 2005

Keywords provided by National Taiwan University Hospital:
TB
PPD
ELISPOT
BCG

Additional relevant MeSH terms:
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections